Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PAT-1251
GB2064 · 2 trials · 2 indications
Incidence and severity of adverse events as reported by investigators
Determination of adverse events will include assessment of vital signs, ECG, clinical laboratory and physical examination
| Arm | Type | Description |
|---|---|---|
| GB2064 | EXPERIMENTAL | GB2064 will be administered orally as 4 x 250 mg tablets twice a day. |
| PAT-1251 Single Dose | EXPERIMENTAL | Oral solution of PAT-1251, 150 - 4000 mg administered once |
| Placebo Single Dose | PLACEBO_COMPARATOR | Matching placebo solution administered once |
| PAT-1251 Multiple Dose | EXPERIMENTAL | Oral tablet(s) of PAT-1251 up to 2000 mg administered daily for 7 days |
| Placebo Multiple Dose | EXPERIMENTAL | Matching placebo tablets administered daily for 7 days |
| Name | Type | Description |
|---|---|---|
| GB2064 | DRUG | GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day |
| PAT-1251 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: Participants must satisfy all of the following criteria at the Screening visit: 1. Adult male or female participants ≥ 18 years of age at enrolment: 1. Female participants may be of non-childbearing potential defined as permanently sterile or postmenopausal, or female parti...
GB2064 is an investigational small molecule being developed for the treatment of myelofibrosis. It is currently in Phase 2 clinical development and is being studied in patients with this condition.
GB2064 is being developed by Galecto, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol DMRA.
GB2064 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. It is currently being evaluated in a Phase 2 clinical trial for myelofibrosis.
GB2064 is being studied in a Phase 2 clinical trial with the identifier NCT04679870. This trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral GB2064 in participants with myelofibrosis. The trial is active but not recruiting participants.
The Phase 2 clinical trial of GB2064 for myelofibrosis has enrolled 21 participants. The trial is being conducted in the United States, Australia, Germany, and Italy, and includes adults aged 18 years and older.